 In Part 1, 72 otherwise healthy participants 18 participants per group, assuming up to 2 dropouts per group with uncomplicated dengue fever meeting the inclusionexclusion criteria will be randomised to receive treatment with placebo, celgosivir or modipafant. Participants will be randomised in parallel to one of Cohorts 1 to 4: 